Long-term efficacy of up to 4 years of therapy with bimekizumab in patients with plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab in BE BRIGHT and BE RADIANT

Long-term efficacy of up to 4 years of therapy with bimekizumab in patients with plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab in BE BRIGHT and BE RADIANT Meeting Abstract

publication date

April 1, 2025

webpage

Web of Science

published in

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT Journal

volume

23